“I suspect that RNAi-based medicines will approach, rival, maybe even exceed what we’ve seen with monoclonal antibodies historically,” says John Maraganore, the CEO of JMM Innovations and founding CEO of Alnylam. He joins Bloomberg Intelligence’s senior pharmaceutical analyst Sam Fazeli to reflect on RNAi’s journey from scientific curiosity to durable drug platform. Maraganore explains Alnylam’s reliance on big pharma partnerships for relatively non-dilutive capital, why rare diseases were the right entry point for commercialization and how mission-first culture sustained the company. He also discusses biotech’s “Sputnik moment,” FDA efficiency and where AI is already delivering real impact in drug discovery.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.